Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania

Antiviral Therapy

Volumn 17, Issue 2, 2012, Pages 265-274

  Mugusi, Sabina F ^a,b   Ngaimisi, Eliford ^b,c   Janabi, Mohamed Y ^a,c   Mugusi, Ferdinand M ^a,c   Minzi, Omary M S ^c   Sasi, Philip G ^c   Bakari, Muhammad ^a,c   Lindquist, Lars ^b   Aklillu, Eleni ^b   Sandstrom, Eric G ^b,c  

^a MUHIMBILI NATIONAL HOSPITAL   (Tanzania)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; LAMIVUDINE; PYRAZINAMIDE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; NIGHT SWEAT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RISK FACTOR; SEX DIFFERENCE; TANZANIA; THRUSH; TREATMENT DURATION; TUBERCULOSIS; WEIGHT REDUCTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CANDIDIASIS, ORAL; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RISK FACTORS; SARCOMA, KAPOSI; TANZANIA; TUBERCULOSIS;

EID: 84860349938     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1956     Document Type: Article

References (50)

1. UNAIDS. UNGASS reporting for 2010 (Tanzania Mainland and Zanzibar). (Accessed 14 January 2011.) Available from http://www.unaids.org/en/ dataanalysis/monitoringcountryprogress/2010progressreportssubmittedbycountries/ tanzania-2010-country-progress-report-en.pdf
2. Ministry of Health and Social Welfare. Tanzania 2010 - National AIDS control Program (NACP). (Accessed 7 February 2011.) Available from http://www.moh.go.tz/NACP
3. Tanzania Commission for AIDS (TACAIDS). Report 2010. (Accessed 31 January 2011.) Available from http://www.tacaids.go.tz/component/docman/doc-download/ 39-newsletter-july-2010.html
4. Tanzania Commission for AIDS (TACAIDS). Tanzania national multisectoral strategic framework on HIV and AIDS 2008-2012: costing. (Accessed 23 November 2010.) Available from http://www.tacaids.go.tz/strategic-documents/tanzanianmsf- 2008-2012-aids-strategy-and-action-plan.html
5. World Health Organization. Global tuberculosis control 2008. Surveillance, planning, financing. (Accessed 7 November 2010.) Available from http://www.who.int/tb/publications/global-report/2008/pdf/fullreport.pdf
6. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999; 28:419-429.
7. Cahn P, Perez H, Ben G, Ochoa C. Tuberculosis and HIV: a partnership against the most vulnerable. J Int Assoc Physicians AIDS Care (Chic) 2003; 2:106-123.
8. Tabarsi P, Saber-Tehrani AS, Baghaei P, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009; 12:14.
9. Lawn SD, Edwards DJ, Wood R. Reducing the burden of tuberculosis presenting during the initial months of antiretroviral therapy in resource-limited settings. Clin Infect Dis 2010; 50:124-125.
10. Girardi E, Palmeri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:326-331. (Pubitemid 32435996)
11. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:42-46. (Pubitemid 44306486)
12. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670-1676. (Pubitemid 39411018)
13. Velasco M, Castila V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
14. Cain KP, Anekthananon T, Burapat C, et al. Causes of death in HIV infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009; 15:258-264.
15. Ansari NA, Kombe AH, Kenyon TA, et al. Pathology and causes of death in a group of 128 predominantly HIVpositive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6:55-63. (Pubitemid 34263546)
16. Rana FS, Hawken MP, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000; 24:23-29. (Pubitemid 30447802)
17. Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7:1569-1579. (Pubitemid 24008849)
18. Mugusi FM, Mehta S, Villamor E, et al. Factors asociated with mortality in HIV-infected and uninfected patients with pulmonary tuberculosis. BMC Public Health 2009; 9:409.
19. Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008; 8:52.
20. Rajagopalan N, Suchitra J, Shet A, et al. Mortality among HIV infected patients in resource limited settings: a case controlled analysis of inpatients at a community care center. Am J Infect Dis 2009; 5:219-224.
21. Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention and switch to second line regimens in antiretroviral-treated patients in sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115-122.
22. MacPherson P, Moshabela M, Martinson N, Pronyk P. Mortality and loss to follow-up among HAART initiators in rural South Africa. Trans R Soc Trop Med Hyg 2009; 103:588-593.
23. Palmieri F, Girardi E, Pellicelli AM, et al. Pulmonary tuberculosis in HIV-infected patients presenting with normal chest radiograph and negative sputum smear. Infection 2002; 30:68-74. (Pubitemid 34293369)
24. Burman WJ, Jones BE. Clinical and radiographic features of HIV-related tuberculosis. Semin Respir Infect 2003; 18:263-271. (Pubitemid 38018770)
25. Mugusi F, Villamor E, Urassa W, Saathoff E, Bosch RJ, Fawzi WW. HIV co-infection, CD4 cell counts and clinical correlates of bacillary density in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006; 10:663-669. (Pubitemid 43845028)
26. Baalwa J, Mayanja-Kizza H, Kamya MR, John L, Kambugu A, Colebunders R. Worsening and unmasking of tuberculosis in HIV-1 infected patients after initiating highly active anti-retroviral therapy in Uganda. Afr Health Sci 2008; 8:190-195.
27. Leone S, Nicastri E, Giglio S, Narciso P, Ippolito G, Acone N. Immune reconstitution inflammatory syndrome associated with Mycobacterium tuberculosis infection: a systematic review. Int J Infect Dis 2010; 14:e283-e291.
28. Komati S, Shaw PA, Stubbs N, et al. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS 2010; 24:1849-1855.
29. Michailidis C, Pozniac AL, Mandalia S, Basnayake S, Nelson MR, Gazzard BG. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 2005; 10:417-422. (Pubitemid 41151019)
30. Kiertiburanakul S. Immune reconstitution inflammatory syndrome in HIV infected patients with tuberculosis. J Med Assoc Thai 2010; 93:257-264.
31. Schoch OD, Rieder HL. Characteristics of sputum smear positive tuberculosis patients with and without HIV infection in a hospital in Zimbabwe. Eur Respir J 1996; 9:284-287. (Pubitemid 26068622)
32. Severo NP, Leite CQF, Capela MV, Simoes MJ. Clinical and demographic characteristics of patients hospitalized with tuberculosis in Brazil between 1994 and 2004. J Bras Pneumol 2007; 33:565-571.
33. Bashi J, Balestre E, Messou E, et al. Time trends in demographic and clinical characteristics of adult patients on HAART initiation in West Africa. Med Mal Infect 2010; 40:449-455.
34. Mankatittham W, Likanonsakul S, Thawornwan U, et al. Characteristics of HIV-infected tuberculosis patients in Thailand. Southeast Asian J Trop Med Public Health 2009; 40:93-103.
35. Hung CC, Chen MY, Hsiao CF, Hsieh SM, Sheng WH, Chang SC. Improved outcomes of HIV-1-infected adults with tuberculosis in the era of highly active antiretroviral therapy. AIDS 2003; 17:2615-2622.
36. Grinsztejn B, Veloso V, Friedman RK, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2009; 23:2107-2114.
37. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
38. Westreich D, MacPhail P, Van Rie A, et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009; 23:707-715.
39. El-Sony AI, Khamis AS, Enarson DA, Baraka O, Mustafa SA, Bjune G. Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection. Int J Tuberc Lung Dis 2002; 6:1058-1066. (Pubitemid 36054959)
40. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Shortterm and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-1725.
41. Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48:829-831.
42. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programs. Lancet 2010; 376:449-457.
43. Dembélé M, Saleri N, Carvalho AC, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIVpositive patients in Burkina Faso. Int J Tuberc Lung Dis 2010; 14:318-323.
44. Rajasekaran S, Raja K, Jeyaseelan L, et al. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile. Indian J Tuberc 2009; 56:69-76.
45. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172:123-127 (Pubitemid 40923324)
46. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 2011; 56:349-355.
47. Mugusi F, Mugusi S, Bakari M, et al. Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience. Trop Med Int Health 2009; 14:1226-1232.
48. Cornell M, Myer L, Kaplan R, Bekker LG, Wood R. The impact of gender and income on survival and retention in a South African antiretroviral therapy program. Trop Med Int Health 2009; 14:722-731.
49. Kipp W, Alibhai A, Saunders LD, et al. Gender differences in antiretroviral treatment outcomes of HIV patients in rural Uganda. AIDS Care 2010; 22:271-278.
50. Holmes CB, Hausler H, Nunn P. A review of sex differences in the epidemiology of tuberculosis. Int J Tuberc Lung Dis 1998; 2:96-104. (Pubitemid 28126063)